NEX-22

About Nanexa

Nanexa is a clinical-stage biotech company on a mission to redefine injectable medicines through its unique nanoengineering platform, PharmaShell®. The company has achieved significant validation through strategic partnerships with industry leaders like Novo Nordisk and AstraZeneca and is progressing proprietary assets toward clinical proof-of-concept. Its dual business model combines internal pipeline development with high-value technology licensing, aiming to capture value in the expansive long-acting injectables market.

About nanexa-ab

Nanexa AB is a publicly traded Swedish biotech focused on revolutionizing drug delivery via its proprietary PharmaShell® platform, which utilizes Atomic Layer Deposition (ALD) to create ultra-long-acting injectable formulations. The company's strategy is dual-pronged: developing its own pipeline of reformulated drugs (most advanced is NEX-20, a long-acting azacitidine in Phase I for MDS/AML) and licensing its technology to major pharma partners like Novo Nordisk and AstraZeneca. With a seasoned leadership team and a platform validated in key therapeutic areas, Nanexa aims to capture significant value in the rapidly expanding long-acting injectables market by improving patient compliance and creating enhanced pharmaceutical products.

Therapeutic Areas